Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.

Kerr, Charles R.; Prystowsky, Eric N.; Smith, Warren; Cook, Laura; Gallagher, John J.

doi:10.1161/01.cir.65.5.869

Cited by 37 publications

(3 citation statements)

References 37 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When I was a cardiology fellow we had quinidine and procainamide to use for maintenance of sinus rhythm. I was fortunate to study the promising new agent disopyramide in patients with the Wolff‐Parkinson‐White syndrome, although no indication for AF was sought 32 . In fact, starting in the 1980s, a plethora of new drugs underwent study and received approval, though none were at first developed primarily for use in AF.…”

Section: Therapymentioning

confidence: 99%

“…I was fortunate to study the promising new agent disopyramide in patients with the Wolff-Parkinson-White syndrome, although no indication for AF was sought. 32 In fact, starting in the 1980s, a plethora of new drugs underwent study and received approval, though none were at first developed primarily for use in AF. Agents such as amiodarone, encainide, flecainide, propafenone, and sotalol initially sought approval for ventricular arrhythmias, while flecainide, propafenone, and sotalol later did appropriate clinical trials to get approved use for AF.…”

Section: Antiarrhythmic Drugsmentioning

confidence: 99%

See 1 more Smart Citation

The History of Atrial Fibrillation: The Last 100 Years

Prystowsky¹

2008

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Atrial fibrillation (AF) has had a rich history that has touched the careers of many of the great clinicians and investigators of the 20th century. More recently, there has been an explosion of research into various aspects of the mechanisms and therapy for AF, as evidenced by over 8,000 publications on AF from 2000 to 2007. A century of research and clinical observations, coupled with modern investigative technologies, has enabled modern investigators to have their own "fantastic voyage" as they travel beyond the cell borders into the ionic mechanisms responsible for AF and its many atrial perturbations. One can only imagine the satisfaction of Wenckebach, MacKenzie, and Lewis if they could see how their seeds of wisdom have grown into such sturdy ideas, or how delighted Scherf would be to learn that his ectopic focus theory for AF has been given new life. This paper on 100 years of AF was initially prepared for presentation as the Plenary Lecture at the AFib Summit for Heart Rhythm 2007 in Denver, Colorado. I have tried to provide the reader with some of the most important observations on AF, realizing that it would be impossible to include all or even most of the major research done during this time frame. I apologize to my many colleagues whose research has helped us to understand better the clinical and basic aspects of AF, yet who could not be cited for lack of space.

show abstract

Section: Therapymentioning

confidence: 99%

Section: Antiarrhythmic Drugsmentioning

confidence: 99%

The History of Atrial Fibrillation: The Last 100 Years

Prystowsky¹

2008

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…A drug was not tested if a patient had previously not responded to it, or if it had been associated with side effects the patient had not tolerated. Conventional drugs [10][11][12] were used first and investigational agents were reserved for resistant cases. When single agents proved ineffective, combination therapy was attempted; generally, a drug active at the atrioventricular node, such as verapamil or propranolol, was combined with another that acted on the accessory pathways, such as a Class I antiarrhythmic.…”

Section: Drug Selectionmentioning

confidence: 99%